InvestorsHub Logo
Followers 155
Posts 2681
Boards Moderated 0
Alias Born 01/29/2004

Re: nobrainerstocks post# 116286

Sunday, 08/20/2017 1:06:33 PM

Sunday, August 20, 2017 1:06:33 PM

Post# of 469764
But What Could Aricept Users Know

Who, in their right mind, would decide upon the efficacy of Aricept by reading the accounts of Alzheimer’s care givers with experience with the drug?

Check ‘em yourself, if you have the intellectual strength to withstand what you read:
https://www.drugs.com/comments/donepezil/

The real experts are here, on this board (of all places) . They state authoritatively that Aricept is plainly a better sigma-1 receptor agonist than Anavex 2-73, that Anavex 2-73 never has and never will surpass the Alzheimer’s treatment outcomes of Aricept.

Likewise, who would so foolishly entertain the thoughts and expressions of both treated Alzheimer’s patients and their family members down in Australia, after many months on Anavex 2-73. It is known, a priori, that since Aricept never produces such phenomenal treatment outcomes, and that Aricept is a much stronger sigma-1 receptor agonist, those Australian accounts must be simply discarded. Either hopeful thinking (placebo effect), all rare, atypical “super responders,” or a corporate contrivance to fraudulently persuade the public that Anavex 2-73 really works.

Glad that’s all resolved now.

I should sell my small AVXL position and get some Pfizer shares, the owner of Aricept. Think I’ll get greater rewards over there? They have a product of such greater therapeutic strength, as we’ve now learned.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News